SAMRATPHPharmaceuticals
Samrat Pharmachem Ltd — Profit & Loss Statement
₹194.95
-7.93%
Samrat Pharmachem Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 60228.71 | 18486.36 | — |
| Tax Rate For Calcs | 0.28 | 0.14 | 0.26 | 0.27 | — |
| Normalized EBITDA | 11.21 Cr | 3.85 Cr | 24.08 Cr | 24.55 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.02 Cr | 68000.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.02 Cr | 68000.00 | — |
| Net Income From Continuing Operation Net Minority Interest | 7.11 Cr | 2.16 Cr | 16.63 Cr | 17.18 Cr | — |
| Reconciled Depreciation | 0.65 Cr | 0.65 Cr | 0.64 Cr | 0.59 Cr | — |
| Reconciled Cost Of Revenue | 266.75 Cr | 270.32 Cr | 281.88 Cr | 193.67 Cr | — |
| EBITDA | 11.21 Cr | 3.85 Cr | 24.10 Cr | 24.56 Cr | — |
| EBIT | 10.56 Cr | 3.21 Cr | 23.46 Cr | 23.96 Cr | — |
| Net Interest Income | -0.67 Cr | -0.69 Cr | -1.05 Cr | -0.54 Cr | — |
| Interest Expense | 0.67 Cr | 0.69 Cr | 0.93 Cr | 0.36 Cr | — |
| Normalized Income | 7.11 Cr | 2.16 Cr | 16.61 Cr | 17.18 Cr | — |
| Net Income From Continuing And Discontinued Operation | 7.11 Cr | 2.16 Cr | 16.63 Cr | 17.18 Cr | — |
| Total Expenses | 276.27 Cr | 279.76 Cr | 287.26 Cr | 197.97 Cr | — |
| Diluted NI Availto Com Stockholders | 7.11 Cr | 2.16 Cr | 16.63 Cr | 17.18 Cr | — |
| Net Income Common Stockholders | 7.11 Cr | 2.16 Cr | 16.63 Cr | 17.18 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 7.11 Cr | 2.16 Cr | 16.63 Cr | 17.18 Cr | — |
| Net Income Including Noncontrolling Interests | 7.11 Cr | 2.16 Cr | 16.63 Cr | 17.18 Cr | — |
| Net Income Continuous Operations | 7.11 Cr | 2.16 Cr | 16.63 Cr | 17.18 Cr | — |
| Tax Provision | 2.77 Cr | 0.36 Cr | 5.90 Cr | 6.42 Cr | — |
| Pretax Income | 9.89 Cr | 2.52 Cr | 22.53 Cr | 23.60 Cr | — |
| Other Non Operating Income Expenses | 0.97 Cr | 1.38 Cr | 0.48 Cr | 0.29 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.00 | -7000.00 | — |
| Net Non Operating Interest Income Expense | -0.67 Cr | -0.69 Cr | -1.05 Cr | -0.54 Cr | — |
| Interest Expense Non Operating | 0.67 Cr | 0.69 Cr | 0.93 Cr | 0.36 Cr | — |
| Operating Income | 9.59 Cr | 1.82 Cr | 23.39 Cr | 23.78 Cr | — |
| Operating Expense | 9.53 Cr | 9.44 Cr | 5.38 Cr | 4.31 Cr | — |
| Other Operating Expenses | 6.65 Cr | 6.58 Cr | 1.02 Cr | 0.80 Cr | — |
| Depreciation And Amortization In Income Statement | 0.65 Cr | 0.65 Cr | 0.64 Cr | 0.59 Cr | — |
| Depreciation Income Statement | 0.65 Cr | 0.65 Cr | 0.64 Cr | 0.59 Cr | — |
| Gross Profit | 19.11 Cr | 11.26 Cr | 28.77 Cr | 28.08 Cr | — |
| Cost Of Revenue | 266.75 Cr | 270.32 Cr | 281.88 Cr | 193.67 Cr | — |
| Total Revenue | 285.86 Cr | 281.58 Cr | 310.65 Cr | 221.75 Cr | — |
| Operating Revenue | 285.86 Cr | 281.58 Cr | 310.65 Cr | 221.75 Cr | — |
| Interest Income | — | 0.28 Cr | 0.18 Cr | 0.14 Cr | 0.09 Cr |
| Diluted Average Shares | — | 0.31 Cr | 0.31 Cr | 0.31 Cr | 0.31 Cr |
| Basic Average Shares | — | 0.31 Cr | 0.31 Cr | 0.31 Cr | 0.31 Cr |
| Diluted EPS | — | 7.00 | 53.83 | 55.62 | 17.26 |
| Basic EPS | — | 7.00 | 53.83 | 55.62 | 17.26 |
| Other Special Charges | — | -0.02 Cr | — | 7000.00 | 0.02 Cr |
| Total Other Finance Cost | — | 0.13 Cr | 0.30 Cr | 0.31 Cr | 0.34 Cr |
| Interest Income Non Operating | — | 0.28 Cr | 0.18 Cr | 0.14 Cr | 0.09 Cr |
| Amortization | — | 9000.00 | 9000.00 | 9000.00 | — |
| Research And Development | — | 30000.00 | 0.00 | — | — |
| Selling General And Administration | — | 1.84 Cr | 1.88 Cr | 1.21 Cr | 1.18 Cr |
| Selling And Marketing Expense | — | 1.29 Cr | 1.51 Cr | 1.01 Cr | 0.78 Cr |
| General And Administrative Expense | — | 0.56 Cr | 0.37 Cr | 0.20 Cr | 0.40 Cr |
| Net Income Discontinuous Operations | — | — | — | 0.00 | 0.00 |
| Write Off | — | — | — | 0.00 | 0.23 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Samrat Pharmachem Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.